Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Developments analyze identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://augustinex445ylh4.idblogz.com/profile